GALE - Galena Biopharma (NASDAQ Stock)

[CatFish]

i got my dividend shares this morning in both accounts. they are a number right now and acording to etrade they are waiting on a symbol and price which i should see in the coming days.

[BadThad]

Beat me again! LOLOLOL

Yea, the divy shares are now showing my account without a symbol. FREE IS GOOD!

[CatFish]

rxii which is RXi Pharmaceuticals showing up at .79 so we are actually green if you got your dividend shares. i even got rxii shares for the gale shares i had sold. so have a lot of rxii lol

[BadThad]

Galena Biopharma Notified That RXi Pharmaceuticals' Common Stock to Commence Trading Under Ticker Symbol "RXII"
6:56a ET May 10, 2012 (Benzinga) Galena Biopharma (Nasdaq:GALE] was notified that RXi Pharmaceuticals' common stock is scheduled to commence trading under the symbol "RXII."

RXi Pharmaceuticals Corporation announced today that the Financial Industry Regulatory Authority, Inc., also known as FINRA, has approved RXi Pharmaceuticals' common stock for trading under the stock symbol "RXII" on the OTC Bulletin Board. RXi Pharmaceuticals anticipates its stock will be eligible for trading commencing today, May 10, 2012.

Free shares now showing in my account properly, $0.09 per share.

[BadThad]

Galena Biopharma Reports First Quarter 2012 Financial Results
4:05p ET May 14, 2012 (GlobeNewswire) Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet medical needs to advance cancer care, today reported its financial results for the quarter ended March 31, 2012 and provided an update on recent business developments.

Operating loss for the three months ended March 31, 2012 increased to $5.6 million, versus $5.2 million for the three months ended March 31, 2011. The increase of $0.4 million in operating loss was due primarily to an increase of $1.5 million for research and development expense partially offset by a $1.1 million decrease in general and administrative expense. Net loss for the three months ended March 31, 2012 was $24.8 million or $0.52 per share, versus a net loss of $3.8 million, or $0.19 per share, for the three months ended March 31, 2011. Other expense for the three months ended March 31, 2012 was $19.2 million, versus other income of $1.4 million. The increase of $20.6 million in other expense was due primarily to an increase of $19.8 million in non-cash expense for the change in the fair value of warrants accounted for as a liability and an increase of $0.8 million in non-cash expense related to the change in fair value of a contingent purchase price consideration liability.

As of March 31, 2012, the Company had cash and cash equivalents of $8.7 million, compared with cash and cash equivalents of $11.4 million as of December 31, 2011. As of April 30, 2012, the Company's cash and cash equivalents totaled $24.9 million.

"With additional funding from our April financing and the recent exercises of a majority of our outstanding warrants, we have approximately $25 million in cash to advance our late-stage cancer immunotherapy pipeline and have significantly simplified our capital structure," stated Mark J. Ahn, Ph.D., President and Chief Executive Officer. "We are grateful for the support of our shareholders throughout our transition over the past year, and we are tightly focused on accelerating our progress and building shareholder value. We continue to add investigational sites and accrue patients into our NeuVax(TM) Phase 3 PRESENT trial, as well as advance clinical studies with both NeuVax in combination therapy and FBP."

Recent Business Highlights

-- Completed $14.5 million public offering of common stock, bringing the
company's cash and cash equivalents to a total of $24.9 million as of
April 30, 2012. Galena intends to use the net proceeds of the offering
for working capital and other general corporate purposes, including the
Phase 3 NeuVax(TM) (E75) PRESENT (Prevention of Recurrence in
Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2
Expression with NeuVax Treatment) clinical trial, Phase 1/2 clinical
trials of Folate Binding Protein-E39 (FBP) and a planned Phase 2 trial
of NeuVax in combination with Herceptin(R) (trastuzumab;
Genentech/Roche).

-- Strengthened intellectual property positions with notices of allowance
for U.S. patents.





- NeuVax patent covers the use for treating Phase 3 target population of low-to-intermediate (IHC 1+/2+) HER2 patients. The patent provides NeuVax exclusivity for this indication until 2028, not including any patent term extensions.

- Composition of Matter patent covers FBP peptide variants for individual or expanded use in combination with the FBP vaccine, E39. The patent provides exclusivity until 2029, not including any patent term extensions, and also protects new methodology of peptide vaccination with wide applicability.

-- Completed partial spin-off of RXi Pharmaceuticals Corporation. RXi is
now operating as an independent, publicly-traded company. A one-for-one
dividend of RXi common stock was recently paid to Galena stockholders.
Galena retains a minority equity interest in RXi along with the
potential to receive up to $45 million in milestones depending on the
development of RXi's product candidates.

Current stock price: $1.12 (down -9.8%)

[BadThad]

Stock taking-off the past 2 days, up almost 20% today.

Current stock price: $1.49

[CatFish]

did i miss something? is thier a reason its been running. i am not complaining by no means because with my divi shares i am about even again

[BadThad]

I couldn't find a reason, it's now down about 12% today. LOL

[CatFish]

looks like gale might be trying to make a move again. up 12.9%. if green again tomorow it will comfirm reversal. lets hope it does

[greencat]

GALE Chart